- Investing Ideas
- Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Australian Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
4
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
4 companies
Telix Pharmaceuticals
Market Cap: AU$5.5b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$16.16
7D
-1.8%
1Y
-13.9%
Mesoblast
Market Cap: AU$3.1b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.35
7D
-4.1%
1Y
-4.1%
Aroa Biosurgery
Market Cap: AU$198.9m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.57
7D
-0.9%
1Y
-10.2%
Avecho Biotechnology
Market Cap: AU$73.4m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India.
AVE
AU$0.019
7D
0%
1Y
216.7%